Outlook Therapeutics Stock News

Outlook Therapeutics (NASDAQ:OTLK) Inc has ended the fiscal third quarter with $26 million in cash and cash equivalents that are expected to fund its work into the first calendar quarter of 2023, in

Outlook Therapeutics (NASDAQ:OTLK) Inc has provided an update on its Biologics License Application (BLA) submission for ONS-5010/LYTENAVA (bevacizumab-vikg) for the treatment of wet age-related macula

Today, we revisit Outlook Therapeutics for the first time since March 2021. The company recently temporarily withdrew its marketing application for its main asset, clouding the outlook on this small-c

Outlook Therapeutics (NASDAQ:OTLK) Inc said it has voluntarily withdrawn the biologics license application (BLA) for its ophthalmic formulation of bevacizumab (ONS-5010 or Lytenava) after the US Food

ISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic for

Outlook Therapeutics (NASDAQ:OTLK) Inc ended its fiscal second quarter with $58.4 million in cash – enough to launch its lead drug ONS-5010 without raising significant additional capital, it said. O

Outlook Therapeutics (NASDAQ:OTLK) Inc has said its chief operations officer Terry Dagnon will discuss the company's wet age-related macular degeneration (AMD) drug Lytenava as part of a panel at the

Outlook Therapeutics (NASDAQ:OTLK) Inc revealed that BioLexis Private Limited, a strategic shareholder in the pre-commercial biopharmaceutical company, is being reorganized and has resulted in GMS Hol

Outlook Therapeutics (NASDAQ:OTLK) Inc said it has submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for ONS-5010, an investigational therapy for the treat

Outlook Therapeutics Inc. (NASDAQ:OTLK) shares, rose in value on Friday, 03/11/22, with the stock price down by -0.56% to the previous day’s close as strong demand from buyers drove the stock to $1.79. Actively observing the price movement in the last trading, the stock closed the session at $1.80, falling within a range of $1.77 … Analysts Predict An Outlook Therapeutics Inc. (NASDAQ: OTLK) Spike? Read More »

Outlook Therapeutics gains 10% as Director Kurt Hilzinger bought 175,132 common shares in the price range of $1.44-$1.49.Mr

Outlook Therapeutics Inc. (NASDAQ:OTLK) has a beta value of 0.81 and has seen 1.99 million shares traded in the last trading session. The company, currently valued at $345.62M, closed the last trade at $1.50 per share which meant it gained $0.04 on the day or 2.74% during that session. The OTLK stock price is -118.0% Weak Fundamental Momentum Pushes Outlook Therapeutics Inc. (OTLK) Lower Read More »

Biotech penny stocks to watch as Ukraine-Russia conflict builds steam. The post Biotech Penny Stocks To Buy For Under $5 As Russia Ukraine Conflict Heats Up appeared first on Penny Stocks to Buy, Pick

Outlook Therapeutics (NASDAQ: OTLK ) reported its Q1 earnings results on Monday, February 14, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Outlook Therapeutics missed estimated earnings by 16.67%, reporting an EPS of … Full story available on Benzinga.com

Outlook Therapeutics press release (OTLK): Q4 GAAP EPS of -$0.08.At December 31, 2021, Outlook Therapeutics had cash and cash equivalents of $70.2 million.